ReviewSkin health and disease2026
Immunological aspects and quality of life among patients with lichen sclerosus.
Review in Skin health and disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- "From inflammation to fibrosis: a proposed role of mucosal-associated invariant T cells in lichen sclerosus - a conceptual framework".Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lichen sclerosus (LS) is a chronic, inflammatory dermatosis that predominantly affects the anogenital region. The ethology of LS is currently regarded as multifactorial, encompassing genetic, autoimmune and tissue remodelling factors, as well as oxidative stress or urine occlusion. Clinical manifestations such as white plaques, atrophic skin, erythema, erosions or varying degrees of sclerosis substantially impair patients' quality of life. It has been indicated that individuals with LS frequently experience feelings of embarrassment, anxiety and social stigma, often resulting from the incorrect association of LS with sexually transmitted diseases. Moreover, the occurrence of sexual dysfunction in this group represents an important clinical concern: patients often refrain from sexual activity due to embarrassment caused by the appearance of the disease, as well as the discomfort associated with it. Recent research indicates that the diminished quality of life observed in patients with LS may arise not only from the direct physical manifestations of the disease, but also from the persistent inflammatory state associated with it. Proinflammatory cytokines, such as interleukin-1, interferon-γ and tumour necrosis factor-α, produced in excessive amounts may adversely influence neurotransmission, thereby contributing to a higher prevalence of psychiatric disorders among patients with LS. The impact appears to involve effects on the metabolism of dopamine, serotonin and noradrenaline. These mechanisms provide a basis for analysing the impact of biologic treatment on patients' mental health. This association highlights the potential for improving patients' outcomes, with regard to somatic symptoms and mental health, through the implementation of targeted anti-inflammatory therapeutic strategies.
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.